Design and synthesis of novel antihypertensive drugs (original) (raw)

Conformational and biological studies for a pair of novel synthetic AT1 antagonists: stereoelectronic requirements for antihypertensive efficacy

Panagiotis Zoumpoulakis

Journal of Pharmaceutical and Biomedical Analysis, 2003

View PDFchevron_right

Synthesis, binding studies and in vivo biological evaluation of novel non-peptide antihypertensive analogues

P. Moutevelis-minakakis, Christoforos Kokotos, T. Mavromoustakos, Panagiotis Zoumpoulakis

Bioorganic & Medicinal Chemistry, 2006

View PDFchevron_right

Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of π*–π* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT1 non-peptide antagonists

John Matsoukas

Bioorganic & Medicinal Chemistry, 2001

View PDFchevron_right

Rational Design and Synthesis of AT1R Antagonists

Andreas G Tzakos

Molecules, 2021

View PDFchevron_right

Structural Insight on the Activity of Type 1 Angiotensin II Peptide Antagonists Using MD Simulations

Hernâni Maia

The Journal of Physical Chemistry B, 2008

View PDFchevron_right

Rational Drug Design and Synthesis of Molecules Targeting the Angiotensin II Type 1 and Type 2 Receptors

Andreas G Tzakos

Molecules (Basel, Switzerland), 2015

View PDFchevron_right

Superimposition of potent non-peptide AT1 receptor antagonists with angiotensin II

John Matsoukas

Letters in Peptide Science, 1996

View PDFchevron_right

Structural comparison between type I and type II antagonists: possible implications in the drug design of AT1 antagonists

John Matsoukas

Bioorg Medicinal Chem Letter, 2000

View PDFchevron_right

American Journal of Phytomedicine and Clinical Therapeutics A Quantitative Structure Activity Relationship Approach to Design Angiotensin II Receptor Antagonists as Antihypertensive Agents by Knn-Mfa

Am Jour of Phytomed & Clinical Therapeut

View PDFchevron_right

Design, Synthesis, Structural Studies, Biological Evaluation, and Computational Simulations of Novel Potent AT 1 Angiotensin II Receptor Antagonists Based on the 4-Phenylquinoline Structure

Maurizio Anzini

Journal of Medicinal Chemistry, 2004

View PDFchevron_right

Differences in Backbone Structure between Angiotensin II Agonists and Type I Antagonists

Amal Wahhab

Journal of Medicinal Chemistry, 1995

View PDFchevron_right

Receptor interactions of the position 4 side chains of angiotensin II analogues: Importance of aromatic ring quadrupole

John Matsoukas

Journal of Molecular Recognition, 1994

View PDFchevron_right

Design, synthesis, and antihypertensive evaluation of 2′-tetrazolyl and 2′-carboxy-biphenylylmethyl-pyrrolidine scaffolds substituted at their N1, C3, and C4 positions as potential angiotensin II AT1 receptor antagonists

Nasser Ismail

Medicinal Chemistry Research, 2014

View PDFchevron_right

Selective angiotensin II AT2 receptor agonists: Benzamide structure–activity relationships

Fred Nyberg, Nicole Gallo-payet, Ulrika Rosenström, Mathias Hallberg

Bioorganic & Medicinal Chemistry, 2008

View PDFchevron_right

Structural Evolution and Pharmacology of a Novel Series of Triacid Angiotensin II Receptor Antagonists.

Kumiko Takeuchi

View PDFchevron_right

N- and C-terminal structure–activity study of angiotensin II on the angiotensin AT2 receptor

Lenka Rihakova

European Journal of Pharmacology, 1998

View PDFchevron_right

Development of angiotensin II antagonists with equipotent affinity for human AT1 and AT2 receptor subtypes

Tomasz Glinka

Bioorganic & Medicinal Chemistry Letters, 1994

View PDFchevron_right

CHIRAL RECOGNITION OF THE ANGIOTENSIN II (ATI) RECEPTOR BY A HIGHLY POTENT PHENOXYPROLINE OCTANOAMIDE

Kumiko Takeuchi

View PDFchevron_right

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor

Nilkanth Patel

The Journal of biological chemistry, 2015

View PDFchevron_right

Structure-activity relationships for the carboxy-terminus-truncated analogs of angiotensin II, a new class of angiotensin II antagonists

MARIA TERESA MARTIN PALOMO

Journal of Medicinal Chemistry, 1990

View PDFchevron_right

Antihypertensive Drugs that Act on Renin-Angiotensin System with Emphasis in AT1 Antagonists

T. Mavromoustakos

Mini-Reviews in Medicinal Chemistry, 2001

View PDFchevron_right

The design and synthesis of a potent angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone angiotensin II

John Matsoukas

Bioorganic & Medicinal Chemistry, 2000

View PDFchevron_right

Biological activity of the novel cyclic angiotensin II analogue [Sar1,Lys3,Glu5]ANG II

John Matsoukas

Letters in Peptide Science, 1996

View PDFchevron_right

The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists

Tomasz Glinka

Bioorganic & Medicinal Chemistry Letters, 1996

View PDFchevron_right

Angiotensin II Pseudopeptides Containing 1,3,5-Trisubstituted Benzene Scaffolds with High AT 2 Receptor Affinity

Adolf Gogoll, Mats Larhed, Gunnar Lindeberg, Fred Nyberg

Journal of Medicinal Chemistry, 2005

View PDFchevron_right

Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3, 5 side-chain bridges: role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists

Panagiotis Zoumpoulakis

View PDFchevron_right

Molecular insights into the AT1 antagonism based on biophysical and in silico studies of telmisartan

T. Mavromoustakos

Medicinal Chemistry Research, 2013

View PDFchevron_right

Leveraging NMR and X-ray Data of the Free Ligands to Build Better Drugs Targeting Angiotensin II Type 1 G-Protein Coupled Receptor

Maria Zervou

Current Medicinal Chemistry, 2015

View PDFchevron_right

Synthesis and biological evaluation of novel antihypertensive compounds

lys mendes

Chem, 2016

View PDFchevron_right

Novel Cyclic Analogs of Angiotensin II with Cyclization between Positions 5 and 7: Conformational and Biological Implications

Garland Marshall

Journal of Medicinal Chemistry, 1996

View PDFchevron_right